当前位置：
X-MOL 学术
›
Nanomed. Nanotech. Biol. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer.
Nanomedicine: Nanotechnology, Biology and Medicine ( IF 4.2 ) Pub Date : 2020-01-10 , DOI: 10.1016/j.nano.2020.102150 Jamshid Gholizadeh Navashenaq 1 , Parvin Zamani 2 , Amin Reza Nikpoor 3 , Jalil Tavakkol-Afshari 4 , Mahmoud Reza Jaafari 5
Nanomedicine: Nanotechnology, Biology and Medicine ( IF 4.2 ) Pub Date : 2020-01-10 , DOI: 10.1016/j.nano.2020.102150 Jamshid Gholizadeh Navashenaq 1 , Parvin Zamani 2 , Amin Reza Nikpoor 3 , Jalil Tavakkol-Afshari 4 , Mahmoud Reza Jaafari 5
Affiliation
|
Myeloid-derived suppressor cells (MDSCs) play a pivotal role in cancer. To overcome the problem of the MDSCs in the tumor microenvironment in this study, a combination of immunotherapy and chemotherapy was used. For this purpose, a liposomal formulation of P5 peptide and PEGylated liposomal doxorubicin (Doxil®) was utilized to treat mice bearing HER2+ tumor model. The results revealed that Doxil® administration before immunotherapy had not only reduced the population and functions of the MDSCs in the spleen (P < 0.001) and the tumor microenvironment (P < 0.05) but had also supported further immunotherapy including enhanced CD4+ (P < 0.01) and CD8+ lymphocyte (P < 0.001) population and IFN-γ production (P < 0.001). This effect was also more pronounced with a liposomal P5 and Doxil® compared with free peptide and doxorubicin. In conclusion, the results demonstrated that Doxil® plus liposomal P5 could have a decreasing effect on MDSCs and tumor growth, and it could be beneficial in breast cancer treatment.
中文翻译：
在乳腺癌小鼠模型中，Doxil化疗加脂质体P5免疫疗法可减少髓样来源的抑制细胞。
骨髓来源的抑制细胞（MDSC）在癌症中起关键作用。为了克服这项研究中肿瘤微环境中MDSC的问题，采用了免疫疗法和化学疗法相结合的方法。为了这个目的，P5肽的脂质体制剂和聚乙二醇化的阿霉素脂质体（Doxil®）被用于治疗带有HER2 +肿瘤模型的小鼠。结果表明，在免疫治疗之前服用Doxil®不仅减少了脾脏MDSC的数量和功能（P <0.001）和肿瘤微环境（P <0.05），而且还支持进一步的免疫治疗，包括增强的CD4 +（P <0.01）。 ）和CD8 +淋巴细胞（P <0.001）群体和IFN-γ产生（P <0.001）。与游离肽和阿霉素相比，脂质体P5和Doxil®的作用更为明显。
更新日期：2020-01-11
中文翻译：
在乳腺癌小鼠模型中，Doxil化疗加脂质体P5免疫疗法可减少髓样来源的抑制细胞。
骨髓来源的抑制细胞（MDSC）在癌症中起关键作用。为了克服这项研究中肿瘤微环境中MDSC的问题，采用了免疫疗法和化学疗法相结合的方法。为了这个目的，P5肽的脂质体制剂和聚乙二醇化的阿霉素脂质体（Doxil®）被用于治疗带有HER2 +肿瘤模型的小鼠。结果表明，在免疫治疗之前服用Doxil®不仅减少了脾脏MDSC的数量和功能（P <0.001）和肿瘤微环境（P <0.05），而且还支持进一步的免疫治疗，包括增强的CD4 +（P <0.01）。 ）和CD8 +淋巴细胞（P <0.001）群体和IFN-γ产生（P <0.001）。与游离肽和阿霉素相比，脂质体P5和Doxil®的作用更为明显。
京公网安备 11010802027423号